BLOG > mRNA & LNP > New partnership with ExploRNA Therapeutics to strengthen our mRNA platform
OZ Biosciences announces a strategic partnership with ExploRNA Therapeutics to strengthen its mRNA platform with next-generation RNA capping technology
Marseille, France – 03/02/2026 – OZ Biosciences, a French biotechnology company specialized in advanced delivery technologies for nucleic acids and cell & gene therapy applications, today announced a strategic partnership with ExploRNA Therapeutics, a biotechnology company developing next-generation co-transcriptional RNA capping technologies (cap analogs) for high-performance mRNA applications.
Messenger RNA (mRNA) and self-amplifying RNA (saRNA) has emerged as a disruptive and highly promising therapeutic platform, enabling cells to produce any protein of interest. Through this collaboration, OZ Biosciences will integrate ExploRNA’s proprietary ExploCap™ technology into its mRNA offering. ExploCap™ is a next-generation co-transcriptional capping reagent designed to generate high-quality capped mRNA with excellent biological properties.
High-quality RNA capping plays a central role in mRNA & saRNA performance, as it directly impacts:
- RNA quality,
- translation efficiency,
- degradation risk by skipping a production step
- downstream manufacturability.
ExploRNA’s next-generation capping reagent ExploCap™ has been designed to flexibly fit various in vitro transcription (IVT) workflows providing reliable high-quality outcomes. ExploCap™ supports both unmodified and modified RNA, and provides a cost-effective alternative to industry-standard capping reagents.
OZ Biosciences brings strong expertise in mRNA and saRNA design, production and commercialization, together with the development and commercialization of proprietary lipid nanoparticle (LNP) formulations for nucleic acid delivery. Combined with ExploRNA’s next-generation capping technologies, this partnership aims to deliver higher-performance mRNA products supporting research, bioproduction, and future therapeutic development programs.”
“This partnership represents an important milestone in strengthening our RNA platform. Integrating ExploRNA’s ExploCap™ technology into our RNA solutions allows us to further improve their quality and performance, supporting our customers as they advance RNA-based research and development programs.” said Olivier Zelphati, CEO of OZ Biosciences.
Jacek Jemielity, CEO of ExploRNA Therapeutics, commented the deal saying “We are excited for OZ Biosciences to become our first partner in delivering high-quality mRNA created with our cap analogs to clients around the globe. We think this collaboration will help scientists researching and developing mRNA-based programs to easily access the benefits of next-generation capping solutions.”
Both companies share a common ambition: to raise the standard of RNA tools available to biotech, pharmaceutical, and academic innovators worldwide, and to support the growing demand for robust, scalable, and high-performance mRNA technologies.
Further updates will follow as ExploCap™-capped mRNA products are progressively integrated into the OZ Biosciences portfolio.
About OZ Biosciences
Founded in 2003 and headquartered in Marseille, France, OZ Biosciences creates, develops, and manufactures innovative molecular delivery systems for the worldwide scientific and pharmaceutical communities. The company’s expertise spans from transfection to transduction technologies, RNA & LNP design and synthesis platforms, adjuvants and assay kits supporting applications ranging from research to cell and gene therapy development.
OZ Biosciences has built a strong portfolio of proprietary technologies, including lipid nanoparticles (LNPs), viral transduction enhancers, and GMP-oriented solutions.
For more information, please visit: https://ozbiosciences.com/
About ExploRNA Therapeutics
ExploRNA Therapeutics is a biotechnology company developing next-generation mRNA technologies, with a strong focus on advanced RNA capping solutions. The company designs proprietary cap analogs that enhance mRNA stability, translation efficiency, and protein expression—key parameters for high-performance mRNA-based applications. ExploRNA’s technologies are compatible with standard in vitro transcription workflows and support the development of mRNA platforms and solutions for pharmaceutical and biotechnology partners.
For more information, please visit: https://explorna.com/
Related Articles
New high-expression Cytokine mRNAs for research
White paper: Ionizable lipids for mRNA-LNP and siRNA-LNP
